Navigation Links
Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Date:9/3/2013

>On August 29, 2013, St. Jude Medical, Inc. (St. Jude Medical) announced that it has bagged the CE Mark approval for its EnligHTN Renal Denervation System which is used to treat patients with drug-resistant uncontrolled hypertension. According to the Company, the new system has an advanced generator that delivers simultaneous ablations through a multi-electrode catheter, which reduces total ablation time from c.24 minutes required by the first generation system to four minutes by the new system. Frank J. Callaghan, President of the St. Jude Medical Cardiovascular and Ablation Technologies Division, said, "The next generation EnligHTN system offers physicians our proven multi-electrode catheter with a new intuitive, faster generator that quickly and effectively delivers consistent ablations with a significant reduction in procedure time. These advancements deliver on our strategy to bring new innovations to a developing market to provide options for patients who currently do not have an adequate treatment for their uncontrolled drug-resistant hypertension." The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ]

Community Health Systems Inc. Research Report

On August 22, 2013, Community Health Systems Inc. (CHS) and Cleveland Clinic announced that they have been selected for exclusive negotiations in relation to the purchase of certain assets of Akron General Health System. According to the Company, the assets include Akron General Medical Center - a 532-bed acute care hospital in Akron, Ohio; 70-bed Edwin Shaw Rehabilitation Hospital in Cuyahoga Falls, Ohio; Lodi Community Hospital - a 25-bed critical access hospital c
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
2. Magellan Diagnostics Receives FDA Clearance for LeadCare Ultra Bench-top Clinical Lead Analyzer
3. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
4. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
7. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
8. MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
9. Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
10. Sanarias Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
11. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a website ... , will celebrate its first anniversary in August. The ... designed to enhance the body,s ability to produce nitric ... is made up of a variety of phytonutrients and ... been found to increase nitric oxide production ...
(Date:7/21/2014)... YORK , July 21, 2014  EHE International, ... exams with a nationwide physician network, today announced that ... Las Vegas, NV has been named an ... the Las Vegas region now ... help proactively maintain their health. "EHE ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
Breaking Medicine Technology:Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... Pfizer Inc,s (NYSE: PFE ) phase III ... CCR5-tropic,HIV-1, increased efficacy was shown as a result ... of the enhanced version of Monogram,s Trofile(TM),Assay., ...
... Oct. 26 Paratek Pharmaceuticals, Inc. today,announced positive ... PTK,0796, a first-in-class aminomethylcycline (AMC). The Phase 2 ... (IV) forms of PTK 0796 to,Zyvox(R) in the ... infections (cSSSIs). Paratek,s trial met its primary safety ...
Cached Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:7/22/2014)... European Bio stimulants Market report defines and segments the ... of revenue. The bio stimulants market in Europe is ... to $940.6 million by 2018, at a CAGR of ... TOC of the Europe Bio stimulants Market report, to ... http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes to 10% of ...
(Date:7/22/2014)... 2014 Today, Therapy Changes announces the start ... – 18 to help increase their knowledge and ability to ... will learn how to make healthy and positive decisions while ... excitement and adventure, but also a time of major life ... Therapy Changes . , “Teens can at times feel ...
(Date:7/22/2014)... 22, 2014 Alliance Storage ... data archiving solutions, has announced the availability of ... archiving solution. The unique new solution merges optical ... on compliant data archiving across all industries including ... The introduction of the new archiving tier permits ...
(Date:7/22/2014)... July 22, 2014 Thought Technology's ... set of simple tools, designed to help clinicians do ... or no experience with biofeedback. The tools in the ... and elucidate any abnormal patterns to teach them to ... paced world, we are familiar with stress and its ...
(Date:7/22/2014)... from the University of Murcia have studied the ... impulsiveness, a personality trait that causes difficulties in ... stimulus and leads to unplanned actions without considering ... an indicator for predicting the risk of behavioural ... from the University of Murcia analyses whether the ...
Breaking Medicine News(10 mins):Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Therapy Changes Announces Teen Support Group Therapy 2Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 2Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 3Health News:Data Archiving Leader Alliance Storage Technologies Releases Enterprise Class Cloud-Integrated Storage Solution 4Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 2Health News:Thought Technology to Present Software for Stress Control at the 2014 American Psychological Association Convention in DC 3Health News:Children's impulsive behaviour is related to their brain connectivity 2
... device that alerts women whether or not they have taken their ... ,The Remember Device developed by Lai Chiu Tang, a student ... to take her pill with a choice of four alerts - ... vibrate mode, reported online edition of BBC News. ,The ...
... will start a health insurance policy next month which will ... that fall under the Phase 1 category will be obliged ... will make the lowest paid the first to benefit from ... the General Authority for Health Services (GAHS) in Abu Dhabi. ...
... Angeles: Pfizer has indicated that recent clinical trials of inhaled ... is found to be useful in regulating blood sugar levels ... Exubera, is slated to be introduced into the United States ... it for use in adults with Type 1 or Type ...
... Mittal it was appropriate for Rahul Mahajan to be taken ... taken to Apollo hospital and not to AIIMS or Safdarjang ... of overdosing. //But medical experts say drug overdosed patients should ... get treated, the better are the chances of their survival. ...
... and the 2004 tsunami, was dealt another blow when ... cultural city, a prime tourist destination. // ... and vibrant arts and crafts scene is second only ... ,"We're suffering another setback," said Wulandari, a hotel receptionist ...
... always painstaking and reaps benefits only when done with full dedication. ... Schlegel in Georgetown. This has brought to the world the first ... was when on June 8, the Food and Drug Administration approved ... strains of HPV. ,In the doctor’s own words, "It's ...
Cached Medicine News:Health News:The myth about government hospitals 2Health News:Indonesian Tourism on Downward Trend After Java Quake 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: